SCHEMBL8097328

SCHEMBL8097328

Cc1nccnc1-c1ccc(Cc2ncc(Cc3ccc(C#N)cc3)[nH]2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRS3 P32247 5/20 0.49
HRH3 Q9Y5N1 1/20 0.42
SCN10A Q9Y5Y9 1/20 0.40
TDO2 P48775 1/20 0.37
NSD2 O96028 1/20 0.36
TYMP P19971 1/20 0.36
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
CYP1A2 P05177 2/20 0.36
CYP2C9 P11712 2/20 0.36
HPGD P15428 2/20 0.36
CYP2C19 P33261 2/20 0.36
MAPT P10636 2/20 0.36
MEN1 O00255 1/20 0.36
RECQL P46063 1/20 0.36
KMT2A Q03164 1/20 0.36
CCNB2 O95067 1/20 0.35
CDK1 P06493 1/20 0.35
CCNB1 P14635 1/20 0.35
GSK3A P49840 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8106523 0.84 BRS3 (0.54) BRS3HRH3SCN10AKDM4EALDH1A1
SCHEMBL7919393 0.81 BRS3 (0.62) BRS3HRH3CYP19A1
SCHEMBL8105207 0.80 BRS3 (0.53) BRS3HRH3SCN10ATSHRHSD17B10
Hydrochloric Acid SCHEMBL8521500 0.80 BRS3 (0.61) BRS3HRH3CYP19A1
SCHEMBL8104996 0.79 BRS3 (0.62) BRS3HRH3
SCHEMBL7919761 0.79 BRS3 (0.57) BRS3HRH3TSHRSMN1; SMN2
SCHEMBL8498703 0.78 BRS3 (0.49) BRS3HRH3SCN10ATYMPKDM4E
Hydrochloric Acid SCHEMBL8307429 0.78 BRS3 (0.61) BRS3HRH3
SCHEMBL8107069 0.78 BRS3 (0.51) BRS3HRH3KDM4EALDH1A1CYP1A2
SCHEMBL8106516 0.77 KIF11 (0.54) BRS3HRH3PTGDR2CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0986302-A1 A METHOD OF TREATING CANCER Merck & Co., Inc. (US) 2000-03-22 EP claimed
EP-0891355-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE Merck & Co., Inc. (US) 1999-01-20 EP claimed
WO-1998054966-A1 A METHOD OF TREATING CANCER MERCK & CO., INC. (US) 1998-12-10 WO claimed
WO-1997036896-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 1997-10-09 WO claimed
EP-0986302-A1 A METHOD OF TREATING CANCER Merck & Co., Inc. (US) 2000-03-22 EP disclosed
EP-0891355-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE Merck & Co., Inc. (US) 1999-01-20 EP disclosed
WO-1998054966-A1 A METHOD OF TREATING CANCER MERCK & CO., INC. (US) 1998-12-10 WO disclosed
WO-1997036896-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 1997-10-09 WO disclosed